Neumora Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Net Income	-235.93	-130.9	-237.31
Depreciation & Amortization	4.02	2.7	1.55
Share-Based Compensation	17.24	8.3	4.27
Other Operating Activities	51.38	5.01	156.07
Operating Cash Flow	-163.28	-114.9	-75.42
Capital Expenditures	-0.12	-0.51	-0.82
Acquisitions	-4.59	-13	0
Change in Investments	69.09	-154.5	0
Investing Cash Flow	64.39	-168.01	-0.82
Share Issuance / Repurchase	235.74	4.27	3.47
Other Financing Activities	-3.8	111.47	290.04
Financing Cash Flow	231.94	115.74	293.51
Net Cash Flow	133.05	-167.17	217.27
Free Cash Flow	-163.4	-115.41	-76.24
Free Cash Flow Per Share	-2.51	-4.24	-0.44

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).